4.8 Article

Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN

Journal

NATURE
Volume 549, Issue 7673, Pages 548-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nature24023

Keywords

-

Funding

  1. Human Frontiers Science Program [LT000284/2013]
  2. Paul F. Glenn Center for Biology of Aging Research
  3. Larry Hillblom Foundation
  4. Wellcome Trust
  5. Francis Crick Institute (Cancer Research UK)
  6. UK Medical Research Council [FC0010048]
  7. Wellcome Trust [FC0010048]
  8. NIH [R01 GM102491, R01GM087476, R01CA174942]
  9. NCI Cancer Center [P30 (CA014195)]
  10. Leona M. and Harry B. Helmsley Charitable Trust [2012-PG-MED002]
  11. Dr. Frederick Paulsen Chair/Ferring Pharmaceuticals
  12. Salk Institute Cancer Center [P30CA014195]
  13. Fritz B. Burns Foundation
  14. Emerald Foundation
  15. Donald and Darlene Shiley Chair
  16. Highland Street Foundation
  17. Cancer Research UK [11581] Funding Source: researchfish
  18. The Francis Crick Institute [10267, 742437-TelMetab] Funding Source: researchfish
  19. The Francis Crick Institute
  20. Cancer Research UK [10048] Funding Source: researchfish
  21. Wellcome Trust [104558/Z/14/Z] Funding Source: researchfish
  22. Wellcome Trust [104558/Z/14/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

Classical non-homologous end joining(1) (cNHEJ) and homologous recombination(2) compete for the repair of double-stranded DNA breaks during the cell cycle. Homologous recombination is inhibited during the G1 phase of the cell cycle, but both pathways are active in the S and G2 phases. However, it is unclear why cNHEJ does not always outcompete homologous recombination during the S and G2 phases. Here we show that CYREN (cell cycle regulator of NHEJ) is a cell-cycle-specific inhibitor of cNHEJ. Suppression of CYREN allows cNHEJ to occur at telomeres and intrachromosomal breaks during the S and G2 phases, and cells lacking CYREN accumulate chromosomal aberrations upon damage induction, specifically outside the G1 phase. CYREN acts by binding to the Ku70/80 heterodimer and preferentially inhibits cNHEJ at breaks with overhangs by protecting them. We therefore propose that CYREN is a direct cell-cycle-dependent inhibitor of cNHEJ that promotes error-free repair by homologous recombination during cell cycle phases when sister chromatids are present.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available